Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ENTPD5_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ENTPD5_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ENTPD5_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ENTPD5_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ENTPD5_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004347021 | Liver | HCC | regulation of carbohydrate catabolic process | 39/7958 | 56/18723 | 3.63e-05 | 3.61e-04 | 39 |
GO:190357822 | Liver | HCC | regulation of ATP metabolic process | 55/7958 | 87/18723 | 7.67e-05 | 6.85e-04 | 55 |
GO:000611021 | Liver | HCC | regulation of glycolytic process | 32/7958 | 45/18723 | 9.63e-05 | 8.34e-04 | 32 |
GO:00464342 | Liver | HCC | organophosphate catabolic process | 89/7958 | 155/18723 | 1.24e-04 | 1.03e-03 | 89 |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:19012921 | Liver | HCC | nucleoside phosphate catabolic process | 49/7958 | 83/18723 | 1.73e-03 | 9.02e-03 | 49 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
GO:004603418 | Prostate | BPH | ATP metabolic process | 120/3107 | 277/18723 | 4.78e-26 | 1.48e-22 | 120 |
GO:000609116 | Prostate | BPH | generation of precursor metabolites and energy | 161/3107 | 490/18723 | 3.05e-19 | 1.45e-16 | 161 |
GO:000989618 | Prostate | BPH | positive regulation of catabolic process | 156/3107 | 492/18723 | 4.50e-17 | 1.11e-14 | 156 |
GO:000645716 | Prostate | BPH | protein folding | 85/3107 | 212/18723 | 2.37e-16 | 4.74e-14 | 85 |
GO:003133118 | Prostate | BPH | positive regulation of cellular catabolic process | 135/3107 | 427/18723 | 7.82e-15 | 1.05e-12 | 135 |
GO:000915018 | Prostate | BPH | purine ribonucleotide metabolic process | 107/3107 | 368/18723 | 1.18e-09 | 5.19e-08 | 107 |
GO:000925917 | Prostate | BPH | ribonucleotide metabolic process | 108/3107 | 385/18723 | 8.73e-09 | 2.97e-07 | 108 |
GO:000616318 | Prostate | BPH | purine nucleotide metabolic process | 109/3107 | 396/18723 | 2.28e-08 | 6.94e-07 | 109 |
GO:001969317 | Prostate | BPH | ribose phosphate metabolic process | 109/3107 | 396/18723 | 2.28e-08 | 6.94e-07 | 109 |
GO:007252118 | Prostate | BPH | purine-containing compound metabolic process | 113/3107 | 416/18723 | 2.77e-08 | 8.13e-07 | 113 |
GO:000645816 | Prostate | BPH | 'de novo' protein folding | 23/3107 | 43/18723 | 3.33e-08 | 9.46e-07 | 23 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ENTPD5 | SNV | Missense_Mutation | | c.1183N>C | p.Asp395His | p.D395H | O75356 | protein_coding | deleterious(0.04) | possibly_damaging(0.781) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ENTPD5 | SNV | Missense_Mutation | | c.412G>C | p.Glu138Gln | p.E138Q | O75356 | protein_coding | tolerated(0.21) | possibly_damaging(0.751) | TCGA-AN-A0XU-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ENTPD5 | SNV | Missense_Mutation | novel | c.804N>G | p.Phe268Leu | p.F268L | O75356 | protein_coding | tolerated(1) | probably_damaging(0.998) | TCGA-GM-A3NW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
ENTPD5 | insertion | Nonsense_Mutation | novel | c.519_520insTATTTAGAGCTGGCTCTCATTTGACAGGTCAGCTGCATG | p.Gly173_Ile174insTyrLeuGluLeuAlaLeuIleTerGlnValSerCysMet | p.G173_I174insYLELALI*QVSCM | O75356 | protein_coding | | | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD |
ENTPD5 | SNV | Missense_Mutation | rs757235389 | c.134N>T | p.Ala45Val | p.A45V | O75356 | protein_coding | tolerated(0.27) | benign(0.037) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ENTPD5 | SNV | Missense_Mutation | novel | c.596A>T | p.Asp199Val | p.D199V | O75356 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UD-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR |
ENTPD5 | SNV | Missense_Mutation | novel | c.987C>A | p.Phe329Leu | p.F329L | O75356 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ENTPD5 | SNV | Missense_Mutation | novel | c.987N>A | p.Phe329Leu | p.F329L | O75356 | protein_coding | tolerated(0.07) | probably_damaging(0.998) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
ENTPD5 | SNV | Missense_Mutation | novel | c.1241N>C | p.Leu414Ser | p.L414S | O75356 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-B5-A1MW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | PD |
ENTPD5 | SNV | Missense_Mutation | novel | c.983C>T | p.Ala328Val | p.A328V | O75356 | protein_coding | deleterious(0.04) | probably_damaging(0.999) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |